Novartis AG ADR (NVS)vsYD Bio Ltd (YDES)
NVS
Novartis AG ADR
$160.50
-0.19%
HEALTHCARE · Cap: $302.86B
YDES
YD Bio Ltd
$4.88
-6.06%
HEALTHCARE · Cap: $422.86M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 4628642% more annual revenue ($57.36B vs $1.24M). YDES leads profitability with a 24.7% profit margin vs 17.5%. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
YDES
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.6%
Fair Value
$95.76
Current Price
$160.50
$64.74 premium
Intrinsic value data unavailable for YDES.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 34.0%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Revenue surging 314.9% year-over-year
Conservative balance sheet, low leverage
Keeps 25 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Trading at 81.3x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.
Bull Case : YDES
The strongest argument for YDES centers on Revenue Growth, Debt/Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at -382.1%. Revenue growth of 314.9% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : YDES
The primary concerns for YDES are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a value stock while YDES is a growth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.45 — expect wider price swings.
YDES is growing revenue faster at 314.9% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 32/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →YD Bio Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Breeze Holdings Acquisition Corp. The company is headquartered in Taipei, Taiwan.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?